erratum report replac earlier version publish today erron state
second bullet front page us stock trade higher price-to-earnings eu peer
error word rather underli analysi correct word
pharmavalu report use valuat six strateg metric
forc rank global pharma/biotech compani market caps/net
present valu npv combin compani market cap
total pharma sale annual spend
pharmavalu proprietari valuat tool pharma industri
offer product-by-product valuat base npv life-cycle drug
long-term record pick major pharma japanes stock base
ev/npv strategi strong market-neutr return
base octob stock screen methodolog produc market-
neutral return decemb major pharma compon
gener return japan pharma
industri takeaway valuat ev/npv line histor
averag despit current high short-term sale growth us eu major npv
valuat continu diverg us major screen expens
ev/npv base lower pipelin valu lower success rate lower exposur
high-growth emerg market higher exposur patent expiri contrast
pe basi reflect short-term ep eu stock look expens
us peer expect similar level pipelin de-risk recent
year slight declin innov level eu us major pharma
major pharma within europ astrazeneca highest overal strateg score
pharmavalu analysi bayer ignor valuat novarti score
lowest base sole pharmavalu ev/npv sanofi clear leader
credit suiss connect seri leverag
except breadth macro micro research
deliv incis cross-sector cross-bord
themat insight client
specialti pharma almiral grifol score highest orion recordati
score lowest
neurocrin biomarin score highest score
lowest albeit level would mid-pack versu global major
japan eisai shionogi score highest dainippon sumitomo taisho
score lowest
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
proprietari valuat model pharma
chang strateg score time
stock screen pharmavalu npv
industri takeaway
eu sustain earn higher driven recent launch em growth
major wave patent expiri emerg
innov averag skew line extens
rate target price
ev/npv valuat rel histori
npv sensit uniqu
top product time
advantag pharmavalu npv approach
limit pharmavalu npv approach
appendix sensit pharmavalu npv discount rate
proprietari valuat model pharma
credit suiss pharmavalu proprietari valuat tool pharma
industri offer product-by-product valuat compani base net present valu
npv life-cycle drug portfolio believ npv valuat
approach particularli valuabl pharma sector predict long-term cash
flow abil captur near-term earn potenti drug market
plu long-term revenu ep potenti drug develop use nine key
data input drive algorithm revenu profit lifecycl drug everi
compani coverag univers
ev/npv methodolog strong record predict major pharma
japan perform octob market-neutr return
five-year market-neutr return global major japan refinitiv
global pharma respect top three major identifi
methodolog octob sanofi roch averag risen
bottom three risen yield market-
neutral return japan pharma top three identifi octob ono
tanab takeda risen bottom three taisho sumitomo
chugai risen averag give market-neutr return
detail figur figur
report set detail conclus rel valuat six strateg
metric believ key long-term success industri
compar global therapeut compani total sale
annual spend year includ us major base evalu consensu data
reincorpor us major biotech analysi
pharmavalu databas on-line pharmavalu regularli updat on-line pleas
contact credit suiss research sale contact discuss on-line access
figur key data input drive pharmavalu algorithm
year millionssalesprofitnpv area profit curv sale gener entri sale gener eros averagelifecycl probabl charl martineau univers toronto decemb
year credit suiss pharma biotech analyst region work togeth screen
lead quot pharma biotech compani number import metric base
standardis approach use pharmavalu databas enabl us compar
compani object number criteria believ import investor
assess strateg strength weak compani approach strip
account differ provid fulli consist approach one agre forecast
probabl success end-us sale region drug
appropri split econom partnership allow standardis
comparison compani irrespect size geograph domicil
score valuat six perform metric combin strateg
matrix base weight paramet believ reflect import
team use data inform view formal stock rate case set
rel team local univers global approach enabl us provid better
overal context investor help us assess like direct futur fund flow within
global pharma industri
year coverag us major pharma in-hous use evalu consensu
forecast us major except case product share cs cover
compani case use estim review us major intend
provid context compani formal coverag score shown
commentari made surround compani taken view
valuat overal pharmavalu univers trade within rel tight band
sinc octob main sector driver appear us polit risk
around drug price lower valuat reflect concern potenti aggress
us healthcar reform valuat peak acknowledg polit gridlock washington
dc us biotech seen biggest valuat rerat reflect return aducanumab
forecast flurri recent biotech focus pre-commercialis compani
acquisit eu pharma compani alder lundbeck ra ucb medicin compani
novarti synthorx sanofi announc
global major pharma valuat remain unchang past month
sector ev/npv around howev hide signific shift
geograph domicil eu major rerat ev/npv off-set
us major de-rat analysi
sanofi score attract global major pharma stock ev/npv fourth
consecut year trade discount npv reflect rel high
contribut cash-gen tail asset world-class vaccin rare diseas franchis
grow dupix franchis gsk roch also look attract ev/npv
valuat appli methodolog evalu consensu estim point
includ celgen exclud allergan unattract ev/npv
within europ novarti novo nordisk score least attract
specialti almiral featur analysi first time make npv cut-
score attract valuat merck kgaa also score well despit
rerat stock cours life scienc divis underpin
npv valuat continu screen least attract follow recordati
biomarin regeneron beigen score attract ev/npv
valuat sarepta galapago score least attract valuat
japan eisai takeda attract otsuka third posit eisai
rise top spot driven reviv aducanumab alzheim partner
chugai retain posit least attract posit held sinc chugai
benefit significantli strong growth royalti incom hemlibra alecensa
share price appear fulli speed npv opportun
price power paramet score uniqu compani portfolio
environ continu us price pressur pbm consolid
threat govern reform budget constraint europ believ view portfolio
uniqu chang give strong insight compani posit
outperform also consid compani exposur sustain off-pat brand
provid altern defenc price pressur strong growth emerg market
roch score top azn also score posit year displac sanofi top
spot last year roch reflect combin benefit recent pipelin success
risdiplam sma tecentriq liver cancer gazyva lupu nephriti legaci biolog
europ move sustain level follow recent aggress eros azn reflect
continu strong growth tagrisso plu potenti farxiga heart failur
anifrolumab lupu roxadustat ckd global basi score
poorli metric base evalu consensu novo nordisk score poorli
year given strong focu competit categori diabet launch oral
semaglutid gradual increas novo uniqu time howev
specialti grifol retain posit leader uniqu
compani gener sale blood plasma busi
consid sustain market decad continu grow high barrier
entri lundbeck ucb orion score poorli uniqu rel peer major
patent expiri forecast impact earli next decad ucb recent
acquisit ra boost uniqu mid-term zilucoplan reach market
lundbeck alder eptinezumab boost uniqu fifth cgrp
migrain market albeit novel quarterli infus administr approach
typic score well uniqu except vertex show
highest level uniqu biomarin neurocrin sarepta also
score well gilead galapago score worst price power year given
competit natur rheumatoid arthriti hepat market
histor japan pharma score poorli uniqu better sustain
brand eisai score well given potenti return aducanumab alzheim
diseas potenti lenvima stand-alone agent combin
keytruda cancer shionogi also score well driven potenti xofluza
influenza hiv portfolio co-market viiv/gsk ono score poorli
uniqu given relianc opdivo keytruda incom consid
discount time highli competit immuno-oncolog market taisho also
replac power reflect abil current pipelin sustain drive growth
rel current market portfolio score pipelin new-launch npv rel
valu establish busi also look product return invest
score metric
azn clear highest scorer third year run ratio recent
launch pipelin establish busi half valu reflect recent
launch tagrisso imfinzi mid-term calquenc cll farxiga heart
failur anifrolumab lupu adjuv trial imfinzi tagrisso drive valu roch
score well recent launch product ocrevu hemlibra tecentriq polivi plu
pipelin contribut risdiplam other novo nordisk also score well given
strong growth potenti ozemp rybelsu diabet end
spectrum bayer struggl replac power despit recent posit data vericiguat
heart failur base evalu consensu bristol myer also
receiv low score owe limit pipelin
specialti almiral stand strongest replac power growth driven
seysara ilumetri skilar pipelin growth tirbanibulin
lebrikizumab strong perform merck kgaa mavenclad tepotinib
bintrafusp alpha ucb even bimekizumab zilucoplan rozanolixizumab
recordati grifol continu score poorli grifol held
back long-term valu plasma busi limit pipelin recordati
typic build growth via acquisit legaci pharma brand result tend score
poorli measur
tend score well replac power limit legaci base busi
high invest pipelin among establish compani benchmark
compar major peer rather emerg biotech name gilead alexion
score strongli transit old new product establish franchis biogen
also score well aducanumab alzheim regeneron benefit dupix still
captur new launch
japan eisai shionogi score highest aducanumab alzheim eisai key
driver wherea shionogi benefit xofluza influenza juluca/cabotegravir hiv
partner viiv depress taisho astella santen
score poorli metric
paramet evalu top-lin growth top-lin growth key preserv
potenti enhanc oper margin view limit top-lin growth often lead
serial restructur order keep margin flat score pharma group growth
astrazeneca retain highest growth score driven oncolog em
growth new-launch potenti farxiga hf anifrolumab calquenc cll
roxadustat novo nordisk also score well ozemp rybelsu drive overal
categori growth base evalu consensu merck lilli also score well
sanofi score poorli continu strong dupix growth off-set haemophilia pressur
volume-bas price eros legaci asset china bayer also score poorli
xarelto growth off-set pressur haemophilia ms
specialti vifor score highest driven continu growth inject iron pipelin
potenti kidney diseas franchis grifol also score strongli driven
strong underli growth blood products/ivig market ucb score worst
metric patent expiri vimpat hold back growth
within establish vertex see strongest growth driven continu roll-
symdeko orkambi cystic fibrosi biomarin also score strongli roll-out
rare-diseas pipelin leverag exist platform opposit end
spectrum gilead score poorli new drug launch off-set declin base
japan ono driven opdivo/keytruda eisai driven aducanumab alzheim
potenti best score compani mitsubishi tanab also score rel well
base potenti plant-bas flu vaccin pipelin dainippon sumitomo
score worst expect see genericis us latuda earli
yet model potenti benefit propos roivant transact may
add pipelin asset close earli
gener risk look proport pharma sale expect erod
result patent expiri also consid differ
forecast eros theoret worst-cas scenario particularli import given
uncertain eros rate surround key biolog drug near mid-term
gsk move top posit analysi modest increment patent
expiri wave hiv patent note gsk see eros
prior expiri advair ventolin expect see increment
competit sanofi novo nordisk astrazeneca also score well basi
base cs evalu consensu forecast expos gener risk
novarti roch bayer bayer assum settlement us
formul patent push xarelto gener beyond period continu
assum eu xarelto eros
specialti grifol score highest high barrier entri plasma
collect fraction drive highli sustain busi merck kgaa also score
well limit patent expiri across portfolio howev assum declin
glucophag concor revenu mid-term chines volume-bas price vbp
expect drive price pressur competit legaci franchis mid-
term downsid ucb score worst given forthcom loss exclus
vimpat neupro lundbeck also score poorli expiri onfi northera
abilifi maintena ipsen also see signific downsid risk given expect entri
somatulin gener within analysi period
alexion highest theoret exposur loss soliri ex-u
us howev us biotech team assum strong franchis retent
sale rapidli move ultomiri settl one tecfidera anda
filer ipr remain resolv still largest overhang
name ip front
japan score compani base forecast gener eros well
exposur long-list legaci domest product ono daiichi sankyo kyowa kirin
santen score well low exposur metric dainippon sumitomo
score badli exposur latuda gener risk mitsubishi tanab remain
uncertainti abil earn royalti gilenya despit on-going attempt partner
novarti settl us patent litig mitsubishi tanab taisho also score poorli
base high proport long-list drug
paramet evalu busi mix may influenc margin develop time
primari care cost-intens market need cover high number prescrib doctor
may includ dtc advertis secondari care less burdensom product prescrib
rel small number doctor may involv less patient choic direct
doctor focu shift primari secondari care period
assum grow exposur secondari care support margin improv time
major pharma astrazeneca roch score highli astrazeneca strong
growth cancer launch drive increas specialti mix time roch
specialti sale mix remain high legaci biolog eros biosimilar off-set
strong growth ocrevu hemlibra tecentriq risdiplam base cs
evalu consensu expect novo nordisk eli lilli continu score poorli
remain heavili expos diabetes/primari care
specialti almiral show greatest improv mix driven
growth potenti specialti dermatolog portfolio tirbanibulin lebrikizumab ipsen
vifor also maintain high proport specialti care revenu time
analysi lundbeck score neg see modest eros specialti mix
patent expiri northera impact revenu success
launch eptinezumab migrain could help off-set drag beyond orion
recordati continu see lowest contribut specialti revenu albeit
stabl across period analysi
compani coverag see near-univers focu specialti care
score highli galapago beigen modest proport
revenu primari care asset
japan chugai see highest overal exposur specialti care also
increas driver includ increment revenu hemlibra
alecensa tecentriq well satralizumab pipelin daiichi sankyo
kyowa kirin show shift toward specialti care product dainippon
sumitomo score worst owe loss exclus specialti product latuda
product concentr import driver margin leverag look percentag
sale deriv compani top-fiv drug compani
increas product concentr like improv oper margin
major pharma retain highest score product concentr fourth year
run top-fiv drug account period
astrazeneca continu show signific improv year analysi growth
forecast tagrisso imfinzi farxiga period lynparza also
becom major contributor tagrisso see major contribut addit
indic adjuv egrfm nsclc well strong em growth gsk
novarti score lowest product concentr howev see balanc
posit margin trend note roch score averag owe fall proport
top-fiv drug howev note increas
margin period attribut grow focu new oncolog
product high-margin rare-diseas product
specialti grifol score highest owe specialis blood product
compani top-fiv drug account sale recordati
orion score lowest top-fiv concentr respect
versu averag recordati top-four drug zanidip urorec toprol signifor
remain unchang orion growth easyhal franchis nubeqa
off-set declin simdax comtan
compani score well owe limit portfolio consist mainli
pipelin asset score worst rel basi owe broader portfolio
declin enbrel neulasta partial off-set growth prolia otezla
chang strateg score time
figur highlight chang overal strateg score major pharma past six
year exclud valuat figur set data ad pharmavalu
ev/npv valuat weight given current restrict bayer exclud
ev/npv data point score group valuat
note steadi improv azn time recoveri roch sinc last
year roch recoveri overal strateg score exclud valuat last year
attribut improv score price power market burden increas
price power driven larg step proport sale come uniqu
sustain product expect key drug herceptin rituxan ex-u
becom classifi sustain brand combin near-term expect
market entri sever novel pipelin molecul market burden roch broad
portfolio newer specialti product ocrevu hemlibra pipelin drug
risdiplam etrolizumab expect help off-set loss biosimilar eros
cancer drug leav roch sustain highest proport specialty/canc
therapi drug major name
azn score slightli dip year see rel less price power vs roch
otherwis remain top scorer half oper measur lower still
above-averag score price power gener risk product concentr
slight uptick gsk strateg score output come
see bayer strateg score declin year influenc enhanc gener risk
compon shift analysi time-frame closer potenti loss exclus
key drug xarelto europ expect earli approach look pharma
divis remind bayer agrochem includ
valuat score bayer group given on-going restrict
figur chang strateg score time paramet
figur chang strateg score time paramet
compani data credit suiss estim us major base evalu consensu data
except partner product sale base cs model
avgsanofigskrochej jmerck aznnovartisnovonordiskpf lilli pharmavalu npv evotheroth health/evnpv mktd /evnpv pipeline/evless attract avgalmirallipsenmerck kgaaucblundbeckgrifolsvifororionrecordaticslpharmavalu npv evotheroth health/evnpv mktd /evnpv pipeline/evless attract charl martineau univers toronto
avgbeigenebiomarinregeneronalexionneurocrinebiogenincytegileadvertexamgensareptagalapagospharmavalu npv evotheroth health/evnpv mktd /evnpv pipeline/evless attract avgeisaitakedaotsukaastellasonod sumitomom tanabeshionogisantentaishodaiichikhkirinchugaipharmavalu npv evotheroth health/evnpv mktd /evnpv pipeline/evless attract charl martineau univers toronto
stock screen pharmavalu npv
pharmavalu npv approach good record screen stock
perform major pharma japan time buy unit
attract compani base sole ev/npv sell unit least attract
compani japan major pharma combin would result market-
neutral return
octob date pharmavalu npv stock portfolio gener
market-neutr return give cumul market neutral return
time period compar perform
respect refinitiv world pharma biotech index
probability-adjust sale pipelin product accur reflect realiti
develop success larg compani portfolio approach
smaller one-product compani investor need consid npv context
binari outcom reason use valuat methodolog
sole metric pick stock either biotech specialti pharma sector
valuat compani alway interest us
detail stock pick use pharmavalu npv methodolog
pleas see pharmavalu strateg conclus report octob
februari updat pharmavalu assess valu
detail past stock pick perform detail figur figur
detail appendix
compani data credit suiss estim data dec
compani data credit suiss estim data dec
compani data credit suiss estim us major pick base cs forecast feb
 yr cum cum rtnmajor pharmatop scorers nordisk scorersbristol nordisk pharm pharm pharm returntot dainippon tanab scorersastella pharmaceut dainippon price chgshare price chgshare price chgshare price chgshare price price chgaverag bottom scorersmajor japan unweight absolut perf portfoliorefinitiv ld pharma/biotech indexrefinitiv world industri indexaverag top scorer averag bottom scorersabsolut perf portfolioal subsector unweight averag top scorer charl martineau univers toronto decemb
industri takeaway
key theme last year pharmavalu conclus valuat
premium us major pharma european major price-to-earnings multipl
particularli use pharmavalu ev/npv metric observ combin
europ superior strateg score richer pipelin outlook led strong prefer
eu major us
follow strong rel stock price perform eu major pharma ytd
eu major us major price-to-earnings multipl revers europ
trade year forward consensu price-to-earnings us
much diverg come perform azn eu major ex azn
trade year forward price-to-earnings consensu expect azn includ lower
externalis gain result improv underli oper profit believ
although realiti real price-to-earnings azn fall appar price-to-earnings rise therefor
show interest eu price-to-earnings base
notabl howev valuat use pharmavalu npv still favour europ
us eu major trade ev/npv versu averag ev/npv consensu
expect us major
figur year forward consensu market cap weight p/e time us vs eu
figur pharmavalu ev/npv time
eu sustain earn higher driven recent
launch em growth
superior npv eu major driven believ greater sustain eu
major earn rel us peer launch cohort analysi figur figur
clearli illustr trend set project revenu time within pharmavalu
databas drug launch cohort time note four key driver greater
sustain eu major pharma revenu
eu major greater exposur emerg market growth especi china
pharma revenu eu major pharma gener asset launch
versu us major partial reflect greater exposur
vaccin sanofi gsk also reflect eu pharma signific greater presenc
emerg market china roch addit legaci oncolog asset onto
nation reimburs drug list nrdl driven unpreced volum growth
offset price declin need achiev nrdl access
roch revenu china revenu increas constant exchang rate cer
look forward prospect volume-bas price vbp china may limit growth
compani particularli larg exposur legaci asset includ
sanofi bayer merck kgaa expect continu strong growth compani
expos innov medicin china includ azn novarti roch figur
highlight sales-weight region growth rate global major pharma overal see
em account one-third increment sale around total sale
global major howev number rise around eu domicil
major versu us major
figur region growth major pharma highlight strong em growth
compani data quarterli report credit suiss research
launch heavili favour eu major second key driver eu major
greater sustain group disproportion exposur recent blockbust
launch eu major pharma forecast add increment
sale drug cohort launch sinc contrast us major expect
add sale period tagrisso imfinzi azn shingrix gsk
roch dupix sanofi repres blockbust launch reach highly-
profit mid-lifecycl phase continu strong growth acceler contribut
margin much modest cohort us launch includ tremfya
skyrizi mani high-profil us major pharma asset keytruda
opdivo ibranc trulic jardianc launch prior includ
cohort cohort begin erod asset see loss
exclus loe time point analysi
probability-adjust pipelin cohort valu broadli similar mid-term
pipelin favour eu third driver higher long-term pipelin eu
forecast increment probability-adjust annual revenu contribut late-
stage pipelin eu major versu us major peer risk-adjust
pipelin valu also similar eu vs us de-risk basi
eu major significantli greater pipelin option reflect higher
proport product pipelin may attribut better disclosur
asset among eu major also notabl spend eu major
forecast significantli ahead us major us major forecast
consensu spend averag sale versu eu major
figur eu major pharma revenu launch cohort
figur us major pharma revenu launch cohort
base evalu consensu data cover compani cse
eu higher level unique/sustain drug fourth driver identifi
higher level uniqu eu compani portfolio provid best
defenc healthcar reform enter us elect cycl highlight
histor under-perform sector ahead us presidenti elect figur
figur us gross net brand drug price rise
mlch adj curr inc sale mlch adj curr inc sale sector rel perfrom month elect daydemocrat-won elect averag elect averag price inflat senatehous presidentdemocratrepublicanbrand list price inflat realis brand price net rebatesreport pharma cpi brand charl martineau univers toronto decemb
healthcar reform expect key area debat
republican democrat centr concern us drug price see news flow
like increas volatil figur figur show sale
expect split level uniqu eu major see current sale
deem either uniqu sustain level rise compound-annual-growth-rate
contrast us major see sale today
unique/sustain level expect stay broadli flat compound-annual-growth-rate
figur eu major breakdown uniqu
figur us major breakdown uniqu
base evalu consensu data cover compani cse
figur set histor top drug world-wide revenu time includ
cs/consensu expect data highlight number key trend
oncolog remain key driver growth keytruda forecast becom
world largest drug revenu opdivo ibranc imbruvica tecentriq make
global top revlimid drop top follow loss
exclus gener competit tagrisso narrowli miss top
rank overal forecast five-year compound-annual-growth-rate immuno-oncolog growth
target oncolog growth
immuno-inflamm includ multipl sclerosi continu key driver
industri sale growth humira forecast remain world largest drug revenu
biosimilar entri erod franchis stelara dupix ocrevu also
featur drug strong growth immune-inflamm larg driven
asset outsid top includ cosentyx lesser extent tremfya
skyrizi fragment reflect new mode action emerg
challeng domin anti-tnf demonstr superior efficaci subset
diabet hidden mega-blockbust novo nordisk eli
lilli forecast among strongest growth driver primari care set
none drug featur global list howev combin revenu
novo semaglutid franchis ozemp rybelsu would rank
world fifth-largest drug franchis sale
figur global drug time end-us sale
major wave patent expiri emerg
one trend support industri growth across geographi limit valu
patent expiri recent year expect trend continu howev
beyond signal sharp increas revenu lost patent expiri
figur set view total product sale risk patent expiri year
univers compani data simpli illustr peak sale product
year patent expiri highlight industri challeng small
molecul biolog loss exclus
main challeng data figur fail take account
gradual eros revenu ex-u small molecul biolog illustr
figur set actual revenu loss patent expiri model forecast
spread gradual eros time forecast sustain
increment drag industri mid-term
figur patent expiri total product valu risk year patent expiri
figur patent expiri actual/expect revenu eros time
innov averag skew line extens
continu believ valu number readout catalyst key
driver sector perform continu stream trial readout hope posit reinforc
innov potenti industri help off-set inevit debat concern
around drug price us major market
readout valu year ago one key observ sharp
reduct readout expect us major expect rebound
data includ ibranc adjuv multipl immune-oncolog adjuv
readout eu major forecast reduct readout
vs howev analysi time
last year forecast line histor averag inflat
valu see result trial read earli calquenc cll
anifrolumab lupu failur duchenn muscular dystrophi readout
product acquir could foreseen sutimlimab
agglutinin diseas sanofi bioverativ acquisit posit breast
cancer azn acquir daiichi sankyo us biotech sharp spike
reflect unexpect reviv aducanumab alzheim
success rate date eu major seen posit outcom
trial line histor averag us major success fallen
risk patent loss mus-moleculeex us-moleculeus-biologicex eros cs forecast us small molecul ex us small charl martineau univers toronto decemb
innov level continu declin major pharma line extens domin
see continu trend toward line extens me-too drug
pivot readout includ adjuv data breast cancer adjuv
immuno-oncolog multipl follow-on immunolog novel readout includ
tezepelumab amgn/azn asthma tirzepatid diabet gefapix
later report figur figur figur highlight sensit
assess npv ev/npv compani analysi late-stag success
failur
figur sale potenti blockbust trial readout peak sale time
compani data credit suiss estim evalu consensu us compani
figur peak sale valu de-risk year level innov
compani data credit suiss estim evalu consensu us compani
 readoutspeak sale potenti prob pivot postivepivot mixedpivot negativepivot pendingno drugsu compani ex biotech eu compani ex biotech select univers blockbust innovationdiamond success rate innov known mechan line extens toosuccess charl martineau univers toronto decemb
rate target price
figur rate valuat stock cover
compani data credit suiss estim us major ep data consensu npv data calcul use drug forecast group item evalu
pharma price decemb
evpric equiti yieldnpvshar npv/shrmajor nordisk pharma pharma dainippon tanab pharma averag pe profit total/ simpl charl martineau univers toronto
introduct npv methodolog
believ npv valuat approach particularli valuabl pharma
sector predict long-term cash flow abil captur
near-term earn potenti drug market plu long-term revenu
earn potenti drug develop product within compani
portfolio differ life-cycle characterist peak sale potenti revenu ramp-
patent expiri schedul gener eros rate captur differ
pharmavalu model drug individu use nine key data input drive
algorithm revenu profit lifecycl drug everi compani
coverag univers calcul npv earn contribut
product-by-product basi sum individu drug valuat combin
valu non-pharma busi gener consum health yield
includ product-focus compani global coverag univers
market-cap cut-off aggreg enterpris valu around
npv valuat time
figur plot aggreg npv bar ev/npv valuat line time
valuat overal univers fell pariti ev/npv sinc
trade tight rang pariti premium identifi asset
figur figur figur show valuat compani
peer also identifi valu mid/late-stag pipelin onward
show impli unidentifi repres differ
ev total npv either posit neg figur figur
current us major pharma coverag key major us compani
assess use evalu consensu forecast key drug key
drug partner cover compani expect base
ytd total assess npv overal univers base compani cover
last year current analysi risen vs
four prior year ev risen vs
four prior year increas npv market drug around
off-set declin valu littl chang valu
busi declin valu npv follow
declin seen declin growth
figur ev versu npv time
year millionssalesprofitnpv area profit curv sale gener entri sale gener eros averagelifecycl probabl line npv time bar npv healthcare/stakesnpv mktd drugsnpv davg ev/npv charl martineau univers toronto
past year global major pharma slightli rerat ev like-for-lik
basi rise assess npv seen biggest
absolut increas ev follow acquisit celgen
premium control see npv base evalu consensu
forecast merck also rise keytruda forecast europ novo
nordisk led way ev npv follow roch ev
npv azn ev npv bayer npv cover
segment analysi owe restrict relat css involv
dispos anim health unit howev note bayer share price
fallen octob period
sanofi score attract ev/npv fourth year run
trade discount npv discount begin
year reflect rel high contribut highli profit
cash-gen tail asset world-class vaccin rare-diseas franchis
emerg dupix franchis us growth like translat
ex us growth time expect focu cost control portfolio
reshap new leadership result re-rat
gsk next cheapest metric current trade discount
npv broadli unchang sinc last year ev assess npv
increas around year gsk merg consum unit
increas valuat strong consum franchis
effect sale line quot global peer
off-set gradual eros valu respiratori franchis advair
ventolin gener yet realli bite
roch seen increas ev year ahead increas
npv leav still trade third-cheapest major pharma compani
group abl upgrad guidanc twice year investor
taken sign confid expect biosimilar
impact us model stronger eros biosimilar
compani suggest see figur figur figur
offset optimist prospect new drug
rais npv
within eu major univers novo nordisk look expens
long franchis valu novo deriv higher proport valu
year mani peer rel penalis discount rate
figur figur highlight rel valuat would chang
discount rate scenario would move novo mid-pack posit
compani data credit suiss estim data us major come evalu apart
data partner product use cs model
figur impli valu time major pharma
avgsanofigskrochej jmerck aznnovartisnovonordiskpf lilli pharmavalu npv evotheroth health/evnpv mktd /evnpv pipeline/evless attract ev d/other identifi dunidentif charl martineau univers toronto
year ad almiral annual analysi assess
group npv reach threshold year longer includ teva
move galapago
almiral screen attract stock investor yet
convinc sustain group dermatolog franchis
earli launch period seysara see current valuat
cover exist franchis see investor effect pay
 asset tackl area greater unmet medic need acn
also serv increas averag valu per unit sale without
view put place infrastructur
merck kgaa move cheapest second-cheapest stock
metric rerat ev/npv pharma
valuat risen much valu life scienc
ucb remain third cheapest univers grow valu
bimekizumab offset effect dilut pay premium buy ra
continu least attract stock ev/npv specialti
pharma univers move premium npv begin
year premium today increas ev match
increas npv grifol close competitor seen similar re-
rate extent npv
figur impli valu time specialti pharma
recordati alway look expens metric pharmavalu set
valu compani creat valu captur growth driven
acquisit recordati strong record growth acquisit
organ cash invest year recordati add
valu ad product establish eu infrastructur also
ad rare diseas special unit although like
orion assess ev risen npv fallen
domest price pressur limit biosimilar take-up below-consensu
expect nubeqa given see limit product differenti
compani seen signific re-rat vifor npv
biggest de-rat almiral ev
npv ipsen ev npv
avgalmirallipsenmerck kgaaucblundbeckgrifolsvifororionrecordaticslpharmavalu npv evotheroth health/evnpv mktd /evnpv pipeline/evless attract ev rom d/other identifi dunidentif charl martineau univers toronto
beigen score attract base high npv pipelin
valu predominantli attribut tislelizumab
opportun nsclc well meaning opportun b-cell
malign use tislelizumab pamiparib combin signific
proport opportun china
biomarin current market portfolio rare diseas enzym replac
therapi vimizim palynziq naglazym account around
npv nearli half valu come project valrox gene
therapi haemophilia account npv
peak npv assum long lifecycl product
meaning patent loss expect mani year
regeneron eylea still account npv around
dupix eylea outsid us partner bayer longer
patent life expect continu sustain end-us sale
provid strong incom see dupix start
life-cycle peak sale around base breadth indic
sarepta sarepta valuat domin pipelin approv indic
exondi account around npv expand
indications/geographi key driver gene-therapi still de-risk
base po peak sale see npv account
npv effect doubl po would move stock
approxim pariti ev/npv
analysi ad evalu consensu otezla sale
addit debt publish model biggest asset npv
prolia/xgeva npv follow repatha neulasta
short-term sale growth driven aimovig npv npv limit
lower margin owe competit natur market share
econom novarti emerg biosimilar franchis also import
npv tezepelumab peak split asthma atop
dermat also interest suffer share econom
figur impli valu time biotech
avgbeigenebiomarinregeneronalexionneurocrinebiogenincytegileadvertexamgensareptagalapagospharmavalu npv evotheroth health/evnpv mktd /evnpv pipeline/evless attract ev d/other identifi dunidentif charl martineau univers toronto
acquisit shire takeda complet earli subsector
seen biggest de-rat ev npv compani re-rat
year ev rise faster npv includ daiichi sankyo mitsubishi
tanab compani de-rat includ dainippon sumitomo eisai takeda
ev npv risen
eisai move attract statu increas po peak sale
aducanumab accord eisai share peak sale
asset po npv group npv lenvima partner
merck second-largest asset account npv leav
eisai short-term success larg hand partner
otsuka de-rat ev fall npv rise npov
increas attribut success otsuka extend tolvaptan
franchis samsca ad jynarqu broaden use polycyst kidney
diseas expect rexulti base stronger long-term expect
us partner lundbeck also drive higher npv
takeda complet shire acquisit enter attract plasma
fraction market see strong demand growth
competitor invest ensur long-term plasma suppli
although entyvio remain biggest singl asset account npv
combin shire asset account drug npv one product
cs well ahead consensu dengu vaccin cse peak
sale doubl evalu consensu
chugai retain posit analysi expens stock see
limit leverag fix econom ex japan sale partner roch
assum reciproc abil access new product roch give
investor increas confid new product flow given abil tap
effect annual pharma
kkirin new entrant one least attract posit
increas ev match declin npv although slightli
optimist margin pegfilgrat khk territori
trim expect ex us crysvita khk lower-than-averag
expect contribut pipelin
daiichi sankyo although third-lowest scorer signific sensit
see figur link larg success partner azn
po peak sale first indic greater
import po sale hold true
promis help low patient po would move daiichi
sankyo much attract ev/npv around
figur impli valu time japan pharma
avgeisaitakedaotsukaastellasonod sumitomom tanabeshionogisantentaishodaiichikhkirinchugaipharmavalu npv evotheroth health/evnpv mktd /evnpv pipeline/evless attract ev d/other identifi dunidentif charl martineau univers toronto
ev/npv valuat rel histori
figur show aggreg ev/npv time variou subsector
follow ev/npv valuat global major specialti
lowest patent cliff septemb valuat
sector improv back sign improv product sinc
earli valuat sector start diverg valuat
differ particularli us eu major share mani characterist
sustain japan pharma enjoy notabl premium valuat factor
may help takeda decis buy shire japan pharma
averag slightli lower rate us major
figur us eu major ev/npv valuat time
biotech univers includ compani addit compani
supplement largest compani cover report new entrant
report beigen neurocrin alder ra left
broader univers acquisit lundbeck ucb respect
npv move specialti pharma move galapago back
specialti pharma reflect cs coverag seen biggest
pickup valu recent perhap reflect recent appetit less
concern immin us healthcar reform broader biotech sector trade
ev/npv substanti rerat three-year averag ev/npv
major trade ev/npv vs three-year averag within
eu major slightli re-rat ev/npv vs three-year
averag contrast de-rat us major current ev/npv
versu three-year averag
japan pharma trade ev/npv vs three-year averag
compani data cs estim us major base evalu consensu post juli
figur pharmavalu ev/npv valuat time
figur figur highlight rel valuat compani within
subsector time compani rank subsector base
ev/npv posit today rel three-year averag analysi eli
lilli compani trade highest ev/npv premium histor norm
novarti eu major trade three-year averag due
cs involv bayer dispos anim health unit shown
current ev/npv histor rang
compani data credit suiss estim us compani use evalu consensu data juli
compani data credit suiss estim note npv us major base evalu
consensu group data individu product forecast partner product base cs forecast
bayer data show histor rang exclud current proce
compani data evalu consensu data credit suiss estim score given bayer
due cs restrict
us price increas critic pharma growth past decad
reach peak rate growth report list price declin
ytd vs figur rebat
continu rise estim net price fallen around
estim base estim ytd averag
list price rise increas rebat lead
brand also first nine month
howev high level us list price figur combin
rise us patient co-pay knowledg ex us price
typic much lower us brought increas polit scrutini
us seem abat yet lower list price rise
expect continu pressur us net price pbm insur continu drive
competit similar product mani new categori cgrp
see multipl competitor within year first entri competit
rebat ensur favour formulari decis build quickli
time clear form us healthcar reform may ultim
implement appear bipartisan support intern refer
price may immedi allevi high patient co-pay
pharmaci drug fuell on-going polit pressur continu
lead higher level rx abandon us elsewher
figur univers sale split level uniqu
product analysi show price pressur start build three
equival drug categori mechan action similar
figur show breakdown sale uniqu within overal
compound-annual-growth-rate sale growth expect univers cover report
see compound-annual-growth-rate uniqu drug current sale growth
account sale deem discount see compound-annual-growth-rate
sale deem sustain brand zero growth remain
figur show strong correl level rebat us
discount list price driven price pressur compar uniqu
compani portfolio compani uniqu product typic report lower
level rebat us believ abl maintain higher price
long term well access patient ultim lead greater
profit saw clear trend show increas
level rebat less uniqu product continu beyond albeit
slightli slower rate continu see compani uniqu
portfolio experienc lowest rebat level
figur compar us rebat price time
drive competit compani compar drug evolv
key way us payer abl reduc price compani uniqu
product greater abil withstand price pressur altern
figur relationship us portfolio uniqu report
figur shift correl uniqu rebat time
product within pharmavalu databas alloc one five categori
base uniqu therefor price power databas assign level
uniqu everi product annual region show separ
forecast level depend mani competitor drug approv
mechan action gener avail either product
equival competitor categoris chang product time
chosen defin uniqu product one maximum
two equival drug gener avail continu believ
health plan wish offer doctor choic least two drug formulari
discount pressur like increas third particip enter
market key risk assumpt one propos reform medicar part
could allow formulari cover one drug per class indic
believ enact medicar part would soon influenc
formulari pattern commerci space score rel contribut
uniqu sustain product econom sale vs peer consid
chang mix
uniqu product two equival drug
mechan action therapeut categori region
sustain brand drug least five year beyond gener entri
high level brand valu typic emerg market lipitor
also captur drug year post patent expiri year post launch
gener avail none expect gamastan grifol imig
brand first launch
discount patent-protect drug least two competitor
mechan action broadli equival label new parp
inhibitor lynparza rubraca zejula
substitut risk/gener risk drug patent protect
class-lead altern gone patent provid opportun switch
 levemir novo post sanofi lantu biosimilar gener risk cover
product sale persist post patent expiri expect gener
entri ventolin hfa gsk us
multi-sourc drug post patent expiri often sale declin owe
gener drug also show growth emerg market
detail definit categori set appendix report
global level roch score highest azn sanofi gsk novarti
roch continu score averag today retain highest proport
sale major pharma uniqu product small
increas last year new product ocrevu
hemlibra among other continu off-set expect loss biosimilar
eros uniqu plu sustain brand high vs
exu herceptin rituxan classifi sustain brand
expect market entri novel pipelin molecul includ
risdiplam sma satralizumab nmosd etrolizumab ibd
global level lowest scorer follow novo
nordisk merck european perspect bayer score lower
european peer
novo continu score poorli measur small proport
product uniqu sustain brand rel peer major
novo portfolio highli competit diabet market space patent
expiri victoza europ us contribut
dilut uniqu upward trend uniqu seen reflect
launch rybelsu oral semaglutid novothirteen
astrazeneca also continu show strong improv proport
pharma sale uniqu sustain drug
driven increas percentag sale uniqu
product uniqu driver cancer product tagrisso
contribut lokelma synagi pipelin asset partner
daiichi roxadustat evrenzo partner
bayer score neutral compar global peer uniqu
second-lowest scorer within univers sale uniqu
sustain brand period expect bayer
score begin suffer xarelto come patent europ howev
may balanc entri uniqu pipelin asset vericiguat vilaprisan
finerenon loxo etc success reach market
figur breakdown pharma sale uniqu statu
figur breakdown pharma sale us uniqu statu
figur breakdown total npv uniqu statu
us econom brand drug sale us uniqueu sustainableu discountableu substitution/gener risku multisourceex us npv bar uniquesustainablediscountablesubstitution/gener riskmultisourceoth charl martineau univers toronto
global level top-two scorer grifol merck kgaa vifor
global level three lowest scorer lundbeck orion ucb
almiral also score posit
grifol continu score highest metric owe
sustain compani plasma busi plasma product
immunoglobulin albumin alpha antitrypsin continu grow averag
per annum despit market decad substitut
gener extrem high barrier entri persist plasma busi enabl
grifol takeda previous shire maintain price
almiral enter analysi year score posit versu peer
price power part driven novel actin keratosi product
tirbanibulin npv expect launch
support array dermatolog brand includ seysara antibiot
acn skilar dimethyl fumar pill psoriasi ilumetri tildrakizumab
inject psoriasi licenc europ potenti lebrikizumab
licenc atop dermat also europ
figur breakdown pharma sale uniqu statu
lundbeck score poorli owe expect northera patent expiri
lack new uniqu product come pipelin trintellix rexulti
abil maintena continu categoris substitut risk post-gener
entri risperd altern dopamin antagonist
recent acquisit alder improv uniqu portfolio given
eptinezumab migrain like fifth cgrp market albeit novel
dose regimen quarterli infus rexulti agit alzheim data
borderlin person disord ptsd launch could help
improv uniqu mid-term
ucb continu score lowest measur sharp declin
uniqu expect owe patent expiri vimpat
cimzia ucb largest product remain subject substitut risk due
biosimilar anti-tnf drug even osteoporosi ucb acquisit
ra pharma import recoveri ucb uniqu mid-
term provid zilucoplan rozanolixumab produc posit phase data
figur breakdown pharma sale us uniqu statu
figur breakdown total npv uniqu statu
us econom brand drug sale us uniqueu discountableu sustainableu substitution/gener risku multisourceex us npv bar uniquesustainablediscountablesubstitution/gener riskmultisourceoth charl martineau univers toronto
typic biotech compani score well uniqu biotech compani
transit development-stag commercial-stag compani tend
base uniqu product compani less differenti product
typic taken larger compani better abl sustain higher
market often need less uniqu competit categori recent
acquisit lundbeck alder good exampl
vertex larger matur biotech compani vertex show highest
level uniqu portfolio focus cystic fibrosi
figur highlight low level rebat regeneron
reflect rebat eylea despit view discountable/non-uniqu
product histor widespread off-label use avastin ophthalmolog
concentr price-sensit segment commerci insur
see two brand product eylea lucenti count three
eylea lucenti avastin design chang
recent launch beovu novarti growth sustain
brand reflect continu sale enbrel post parent expiri ex us aranesp
gilead lowest scorer rate hiv drug discount
strong competit gsk viiv number possibl regim
patient follow
figur breakdown sale uniqu statu
figur breakdown us sale uniqu statu
figur breakdown total npv uniqu statu
us econom brand drug sale us uniqueu discountableu substitution/gener risku multisourceex us npv bar uniquesustainablediscountablesubstitution/gener riskmultisourceoth charl martineau univers toronto
japanes sector typic score poorli uniqu higher
sustain brand long-list product remain import domest
driver year patent expiri
eisai high scorer base probability-adjust sale aducanumab
share po peak potenti also lenvima
potenti new cancer drug amatuximab po peak sale
shionogi see improv uniqu base xofluxa influenza
potent successor tamiflu co-market roch dual
agent hiv drug sold via viiv jv
figur breakdown japan pharma sale uniqu statu
ono score poorli uniqu owe high relianc opdivo
incom npv npv royalti keytruda
despit current differenti label design
oncolog drug discount
taisho biggest singl asset pure domest portfolio remain
edirol osteoporosi prospect gener
observ dainippon sumitomo strong appar improv
percentag uniqu artefact expect loss us latuda
risk gener entri sinc expect entri
februari
figur breakdown pharma sale us uniqu
figur breakdown total npv uniqu statu
us econom brand drug sale us uniqueu discountableu substitution/gener risku multisourceex us npv bar uniquesustainablediscountablesubstitution/gener riskmultisourceoth charl martineau univers toronto
npv sensit uniqu
highlight sensit compani price pressur flex
element drug npv deriv categori uniqu sustain
product show chang total group npv reduct valu
drug chart
within major pharma europ novo nordisk see highest risk come
possibl competit off-pat glp payer could look enforc
gener first approach diabet care
within special lundbeck show highest sensit driven gener risk
highest npv product trintellix rexulti abilifi maintena
figur major pharma pv sensit reduct discount substitut risk multisourc drug categori
figur specialti pharma pv sensit reduct discount substitut risk multisourc drug categori
npvdiscountablesubstitution/gener npvdiscountablesubstitution/gener charl martineau univers toronto
figur biotech pv sensit reduct discount substitut risk multisourc drug categori
figur japan pharma pv sensit reduct discount substitut risk multisourc drug categori
npvdiscountablesubstitution/gener npvdiscountablesubstitution/gener charl martineau univers toronto
pharma industri characteris product cycl major drug
experienc year market exclusivity/pat protect drug compani
need invest continu rejuven portfolio therefor product
key review pharma sector product look chang npv
 versu spend cse peak sale fda approv drug trial
success late-stag time score compani replac power
look abil current pipelin drive growth also consid
 product compani similar pipelin valu invest
product would differ replac power one long life-cycle
base busi base portfolio see strong gener eros
global product npv spend seen slight rebound
two year poor perform figur global declin
attribut increas spend coupl decreas
npv year global increas product driven larg
europ see increas use calcul product
ad better rel european perform increas spend
use seven-year averag modest europ compar
us specialti japan
figur us approv credit suiss peak sale launch year
figur show high valu drug term peak sale opportun
estim approv fda increas
approv far year includ rybelsu novo
diabet rinvoq rheumatoid arthriti skyrizi plaqu psoriasi
mayzent novarti rrms/spm zolgensma novarti gene therapi sma
meaning line extens includ dupix sanofi adolesc atop
dermat calquenc r/r cll valu biolog product approv
figur show peak valu potenti pivot data readout estim total
peak sale potenti drug pivot data readout
materi step-up five-year averag
 success rate significantli lower previou five-year
averag larg driven mix neg data biotech
space three alzheim trial biogen/eisai drug
elenbecestat deem failur aducanumab resurrect po
peak therefor inflat valu us pharma
continu see notabl declin success rate posit vs
mainli attribut neg cancer trial eu pharma
maintain success rate similar past four year
consid first time expect valu pivot readout
meaning higher expect
perform analysi last year five-year averag
note valu tend increas year earli readout
consid level innov proport innov
readout global line five-year averag eu pharma
remain innov us pharma figur
 yr spendu larg capeu larg capjapanspecialtyglobalu prob number new launch spot us peak sale yr us lch bar sale nda sale s-nda sale bla sale s-bla sale bla-b sale etcpeak sale us overallu charl martineau univers toronto
figur sale potenti pivot clinic trial year
compani data credit suiss estim us data base evalu consensu
figur innov total valu pivot trial vs success rate
compani data credit suiss estim us data base evalu consensu
 readoutspeak sale potenti prob pivot postivepivot mixedpivot negativepivot pendingno drugsu compani ex biotech eu compani ex biotech select univers blockbust innovationdiamond success rate innov known mechan line extens toosuccess charl martineau univers toronto
figur global sale potenti pivot readout
compani data credit suiss estim contain us data base evalu consensu
figur global sale potenti readout
compani data credit suiss estim contain us data base evalu consensu
npv pipelin launch vs npv market replac power
measur look npv pipelin recent launch product relat
npv current establish busi includ recent launch
product numer valu still carri execut risk unlik
contribut current profit group still benefit
recent spend believ investor will pay premium compani
npv weight toward pipelin recent launch product
investor may focu high probabl npv recent launch product
other may focu probability-adjust long-term npv
npv recent launch jan near-term pipelin long-term pipelin
npv establish drug launch dec
npv pipelin launch vs spend product
measur look npv data instead use valu
establish busi denomin use spend give sens
level invest requir gener npv
npv recent launch jan
npv pipelin
npv spend
analysi tri includ full spend includ capitalis
ifr process us well regular spend
captur full invest exampl includ in-process
 expens collabor payment top non-gaap addit
book includ novarti avexi aaa acquisit
sanofi bioverativ ablynx ad
acquisit array lilli cover part cost
loxo lundbeck alder also add novarti acquisit
medicin compani ucb acquisit ra
sales/r spend product score
also detail histor vs futur product term product peak sale potenti
vs invest show probability-adjust peak sale potenti three
time period recent cover launch current
futur divid lag total invest full probabl
set provid view option
impact npv valuat failure/success asset
develop asset bring signific degre risk around pivot trial
result earli commercialis univers compani set
npv sensit pipelin success failur phase file asset
exclud high-risk late-stag asset probabl success
typic neg data observ trial still
run complet
term true product novo nordisk score highli recent
product owe launch rybelsu coupl low
spend rel global peer azn also score well
slightli lower industri spend second-highest npv recent
launch roch roch high spend rel industri
averag prevent score higher almiral score well global specialti
pharma mainli owe low spend
 readoutspeak sale potenti prob pivot postivepivot mixedpivot negativepivot pendingno innov known mechnaism line extens toosuccess charl martineau univers toronto
global level top scorer azn follow roch novarti
astrazeneca strongest replac power major pharma reflect
numer new product drive growth npv recent
launch product continu driven tagrisso nsclc imfinzi stage
nsclc calquenc cll near-term pipelin also includ
breast cancer roxadustat chronic kidney diseas long-term valu
propel forward azn potenti play meaning role adjuv
oncolog treatment tagrisso imfinzi
roch also score well strong replac power reflect group
declin establish busi biosimilar eros off-set recent launch
product includ ocrevu ms hemlibra haemophilia tecentriq
polivi blood cancer risdiplam sma ipatasertib
oncolog main contributor longer term pipelin valu
novo score well larg inclus ozemp rybelsu
count recent cohort although high valu base busi
limit replac power possibl novel high-pot obes drug still
far away make make impact year novo score well recent
 product figur
bayer score lowest follow sanofi lilli
bayer lowest replac power major pharma mostli owe
substanti contribut xarelto npv base busi compani
npv patent expir eylea amd/dm npv
model limit valu uplift bayer newli launch nubeqa prostat cancer
late stage pipelin vericiguat cv
sanofi also score averag attribut larg base
establish product core vaccin busi togeth boost
denomin analysi mask strong growth dupix still partli
short-term numer
power ratio npv d/npv establish drugsnpv recent ches/establish drugsnpv nt pipe /establish drugsnpv lt pipe/establish charl martineau univers toronto
figur replac power recent vs futur product npv launch pipeline/r spend
figur product recent current futur peak sales/relev spend
power npv d/npv spendrec product npv lch spend product npv lch npv sale /lag periodsr productivityadd charl martineau univers toronto
global level top scorer almiral follow merck kgaa ucb
recordati score lowest within specialti name grifol
orion
almiral unsurprisingli strong replac power valu given new drug
specialti higher-valu product contrast eros part
base busi aczon first gener expect end growth driven
newli launch seysara ilumetri skilar expect pipelin specialti
drug tirbanibulin actin keratosi lebrikizumab atop dermat boost
increment sale
orion score mainli driven expect growth recent approv
therapi nubeqa prostat jv bayer compani npv
merck kgaa solid replac power driven new product mavenclad
ms bavencio cancer pipelin asset bintrafusp alpha cancer jv
gsk replac power also benefit declin rebif franchis
base franchis uncertainti stabil larg
glucophag franchis expect sale could risk
ucb boost recent acquisit ra pharma build
continu long-term valu driven plasma fraction
busi product includ immunoglobulin albumin plasma-deriv factor
limit impact pipelin main pipelin product
dyslipidaemia
recordati limit pipelin product intern develop portfolio
compani histor sought acquisit bolster portfolio despit
recent acquisit rare-diseas asset signifor osilodrostat
novarti poor replac power reflect high npv base
busi expect continu drive growth yet
recordati demonstr record launch asset new specialti
grifol similar success legaci plasma fraction
busi set high bar replac power grifol interest
project develop look use plasma/ig alzheim
alloc po drive increment peak sale
see clinic studi need drive reimburs
power ratio npv d/npv establish drugsnpv recent ches/establish drugsnpv nt pipe /establish drugsnpv lt pipe/establish charl martineau univers toronto
figur replac power recent vs futur product npv launch pipeline/r spend
figur product recent current futur peak sales/relev spend
power npv d/npv spendrec product npv lch spend product npv lch npv sale /lag periodsr productivityadd charl martineau univers toronto
young compani no/limit base busi definit score well
replac biotech compani probabl relev focu
return invest see figur also score well
establish peer case reflect focu specialti
drug high price limit market expens biolog typic long
effect patent live drive high return also survivor bia
compani reach market cap cut-off inclus
divid univers establish emerg compani
emerg compani score maximum mark replac power show na
chart
highest scorer look establish compani benchmark
compar matur major
alexion gilead score well transit one gener product
anoth effect replac denomin numer therapi
area limit addit market cost
replac power much tie potenti success
aducanumab without asset would score averag
beigen new entrant year team hong kong forecast strong
local adopt tiselizumab us sale togeth
zanubrutinib recent approv us mantl cell lymphoma
neurocrin anoth new entrant major valu deriv
ingrezza tardiv dyskinesia launch
lowest scorer look establish compani establish
score poorli rel major peer see figur analysi amgen
driver growth term increment sale older drug
prolia repatha togeth biosimilar humira newli acquir otezla
poor replac score reflect scale base busi
growth continu domin jakavi first launch
major growth forecast come exist indic forecast
limit increment sale new drug
pemigatinib due launch
power ratio npv d/npv establish drugsnpv recent ches/establish drugsnpv nt pipe /establish drugsnpv lt pipe/establish charl martineau univers toronto
figur replac power recent vs futur product npv launch pipeline/r spend
figur product recent current futur peak sales/relev spend
power npv d/npv spendrec product npv lch spend product npv lch npv sale /lag periodsr productivityadd charl martineau univers toronto
japan pharma tradit score poorli rel peer metric larg
believ stabil base earn rais denomin
compar product base npv pipelin npv
spend differ less obviou although still see lower return japan-
domicil compani major peer key compani
highlight strong return includ eisai chugai return
come larg newli launch hemlibra
eisai replac power come larg share
aducanumab interest peak sale po outsid
asset eisai would low replac power rel peer
shionogi replac power split short- medium-term
asset short-term asset xofluza group new influenza treatment
product partner roch cs global peak sale new hiv
asset juluca/cabotegravir sold via viiv jv gsk largest
medium-term asset earli stage depress drug team
see peak potenti albeit po today
daiichi sankyo drive growth partner
azn forecast global sale initi file indic
metastat breast cancer greater valu would follow-on
indic low breast cancer see
potenti current po
taisho
pipelin
ozoralizumab ra in-licens japan po peak
potenti drug depress po peak
astella launch forecast renal cancer po
fezolinet menopaus symptom po peak
otsuka otsuka three signific mid stage asset highest profil
one-third interest akebia vifor vadadustat renal dialysi
us broader ex us right drug nmda antagonist
alzheim would potenti import group ascrib
po global peak sale
santen key develop stage asset micro shunt drain
eye treat glaucoma approv eu us would key market
santen wish build capabl support launch
power ratio npv d/npv establish drugsnpv recent ches/establish drugsnpv nt pipe /establish drugsnpv lt pipe/establish charl martineau univers toronto
figur replac power recent vs futur product npv launch pipeline/r spend
figur product recent current futur peak sales/relev spend
power npv d/npv spendrec product npv lch spend product npv lch npv sale /lag periodsr productivityadd charl martineau univers toronto
figur figur show sensit current group npv chang
probabl success late-stag rang possibl ev/npv
would result full success failur late stage darker element
bar look impact move either success failur
drug current assum probabl success least
white extens bar cover drug current probabl success
black squar repres current ev/npv alongsid npv chart
show similar data focu flex valuat group ev/npv
bottom bar repres ev/npv group would move
 success top bar repres ev/npv full pipelin failur
azn shown highest sensit past year
retain posit today sensit includ success/failur
peak variou set po superior
imbruvica calquenc increment global sale
despit complet still give azn po
roxadustat given unknown view regulators/pay
roch increas sensit visibl earlier stage asset improv
probabl success show analysi
asset includ adjuv tecentriq po peak adjuv
cancer well risdiplam peak sma huntington
peak analysi includ sensit
gantenerumab po alzheim given low
probabl success
much separ compani term npv sensit
orion ucb margin highest sensit
orion sensit surround expand indic nubeqa metastat
prostat cancer downsid upsid given current po
increment local sale orion partner bayer
across total opportun zilucoplan po peak
sale rozanolixizumab po across indic
highest sensit development-stag compani effect binari
galapago one lead asset filgotinib global peak sale
domin today prospect aducanumab assum
po peak sale econom share eisai
sarepta numer addit dmd drug po differ
eisai highest sensit reflect po aducanumab
partner
figur npv downside/upsid failure/success drug
figur ev/npv valuat rang failure/success drug
compani data evalu consensu data credit suiss estim use forecast base
compani data credit suiss estim use forecast base evalu consensu
figur npv downside/upsid failure/success drug
figur ev/npv valuat rang failure/success drug
ev/npvnpv upside/downsid late-stag pipelin catalyst chang npv poschg npv posev/npv today top avgsanofigskrochej jmerck aznnovartisnovonordiskpf lilli pharmavalu ev/npvlegendev npv valuationshad bar -impact success/failur drug prob dot bar -impact success/failur drug avgalmirallipsenmerck kgaaucblundbeckgrifolsviforrecordatiorioncslpharmavalu ev/npvnpv upside/downsid late-stag pipelin catalyst chang npv poschg npv po ev/npv today top ev/npvlegendev npv valuationshad bar -impact success/failur drug prob dot bar -impact success/failur drug charl martineau univers toronto
figur npv downside/upsid failure/success drug
figur ev/npv valuat rang failure/success drug
figur npv downside/upsid failure/success drug
figur ev/npv valuat rang failure/success drug
avgbeigenebiomarinregeneronalexionneurocrinebiogenincytegileadvertexamgensareptagalapagospharmavalu ev/npvnpv upside/downsid late-stag pipelin catalyst chang npv poschg npv po ev/npv today top avgbeigenebiomarinregeneronalexionneurocrinebiogenincytegileadvertexamgensareptagalapagospharmavalu ev/npvlegendev npv valuationshad bar -impact success/failur drug prob dot bar -impact success/failur drug avgeisaitakedaotsukaastellasonod sumitomom tanabeshionogisantentaishodaiichikhkirinchugaipharmavalu ev/npvnpv upside/downsid late-stag pipelin catalyst chang npv poschg npv posev/npv today top avgeisaitakedaotsukaastellasonod sumitomom tanabeshionogisantentaishodaiichikhkirinchugaipharmavalu ev/npvlegendev npv valuationshad bar -impact success/failur drug prob dot bar -impact success/failur drug charl martineau univers toronto
paramet look top-lin growth brand pharma
figur figur show strong relationship revenu growth
sector rel rate local market
long held view medic inflat run
compani consist top-lin growth level reason
opportun preserv potenti enhanc margin consist sale growth
level would requir serial restructur keep margin flat ultim top-
line growth critic long-tim success
section look growth brand pharma busi context
overal group sale
figur us revenu growth time
score compani look expect growth base
split portfolio differ cohort illustr contribut growth
establish drug recent launch product execut risk may still
issu probability-adjust pipelin also show upsid
use econom sale rather report sale growth account
jv partnership captur impact profit-shar arrang
exampl methodolog correctli reflect econom ocrevu roch
receiv total end-us sale us although roch
book end-us sale econom share score
compani trajectori probability-adjust sale growth take account
group pharma growth rank adjust posit pipelin
figur pe rel key subsector
overal see four-year sale growth without pipelin
potenti compound-annual-growth-rate late-stag pipelin success
compani would expect grow fastest base probability-
adjust pipelin azn novo us evalu consensu forecast
suggest strongest growth lilli merck
astrazeneca driven cohort recent launch drug tagrisso
lynparza imfinzi calquenc make continu
base busi eros geograph roll-out count recent launch
indic extens drug fall pipelin compon
also includ posit breast cancer
roxadustat ckd
novo nordisk growth driven share gain diabet compani
point market growth around share gain
year bring expect diabet growth obes growth
top littl true pipelin growth novo time-frame
potenti potent obes drug like launch
compani expect show lowest pharma growth sanofi
sanofi suffer larg establish pharma busi total
close one-third sale em grow
develop market declin overal
declin per annum repres signific headwind analysi
sanofi credit dupix reflect econom interest
bayer exist pharma sale stabl growth xarelto
expect larg off-set declin haemophilia betaseron
franchis cautiou nubeqa sale given see limit product
differenti see option vericiguat partner
merck recent posit top line data
sustain novarti growth depend time gilenya patent
expiri us
compani data credit suiss estim base evalu consensu
oper margin line index drug sale -econom bar establish drugsrec lchespipelin inc sale probhealth/pharma charl martineau univers toronto
compani data credit suiss estim base evalu consensu data
figur breakdown sale molecul type
compani data credit suiss estim base evalu consensu
oper margin line index group sale -rep bar drug salesoth salesgroup margin line brand drug salessmal moleculesimpl biologiccomplex biologicvaccin biosimilar gene therapi cell therapyhc op charl martineau univers toronto
ucb see patent expiri vimpat tough environ
cimzia grow use biosimilar compet ra biolog even
key new short-term drug partner long-term interest
psoriasi biolog bimekizumab new immunolog franchis lead
indic myasthenia gravi group fcrn zilucoplan
acquir ra pharma
recordati grow typic acquisit organ
model acquisit see analysi typic penal group
rel peer may spend overal amount invest
busi via visibl asset recordati cash
invest low histor invest equival percentag free
cash flow growth via acquisit peer
global level look compound-annual-growth-rate univers
exist drug new launch
success compound-annual-growth-rate would rise
growth
exist
injectafer/ferinject launch us build exist venof
franchis continu grow strongli acquisit veltessa
sanofi togeth us joint ventur freseniu
distribut product kidney dialysi drug develop kidney expertis
help in-licens new product space
ccx vadadustat akebia
margin pip grifol growth grifol suffer drag declin
human factor sale see strong vaccin growth unit
bought novarti also show meaning amount recent launch
product growth haegarda key pipelin asset
high lipid po current grifol
po increment albumin/ig sale use alzheim
oper margin line index drug sale -econ bar establish drugsrec lchespipelin inc sale probhealth/pharma charl martineau univers toronto
figur breakdown sale molecul type
oper margin line index group sale -report bar drug salesoth salesgroup margin line brand drug salessmal moleculesimpl biologiccomplex biologicvaccin biosimilar gene therapi cell therapyhc op charl martineau univers toronto
growth biotech realli need split matur compani
emerg compani compar compani well-establish portfolio
market sale today alexion regeneron
major pharma see establish biotech project deliv lower sale growth
major pharma univers compound-annual-growth-rate
figur breakdown growth technolog highlight specif
growth gene therapi sarepta biomarin
regeneron dupix remain key driver growth sale growth driven
indic expans geograph roll-out libtayo also partner
sanofi second-biggest driver time-frame
off-set expect declin eylea
period see growth prolia/xgeva repatha
off-set declin neulasta enbrel us biotech team
believ enough credit given group biosimilar franchis
highest scorer establish
alexion growth come group continu grow pnh franchis
transit soliri ultomiri key date patent expiri soliri
lowest scorer establish
gilead see limit overal growth growth biktarvi latest hiv combo
drug come larg extent trade within group older portfolio
patent expiri truvada bring loss sale
perhap surprisingli given group share aducanumab cs
po peak eisai see stronger growth
probabl sale larg off-set expect strong eros tecfidera avonex
rituxan incom clear debat remain level eros spinraza
new drug risdiplam roche/ptc
oper margin line index drug sale -econom bar establish drugsrec lchespipelin inc sale probhealth/pharma charl martineau univers toronto
figur breakdown sale molecul type
oper margin line index group sale -report bar drug salesoth salesgroup margin line brand drug salessmal moleculesimpl biologiccomplex biologicvaccin biosimilar gene therapi cell therapyhc op charl martineau univers toronto
japan pharma compound-annual-growth-rate probability-adjust basi
level slightli higher expect global peer howev
heavili influenc higher expect pipelin valu particular strong
growth eisai base probability-adjust sale aducanumab
tanab japanes team forecast strong sale group flu
vaccin exclud new pipelin contribut underli growth univers
would par global major
compani higher-than-averag growth ono eisai
eisai key potenti driver interest aducanumab po
peak sale key driver on-market drug lenvima
expect add increment sale ono growth come
direct local sale opdivo japan royalti oversea sale opdivo
lower rate keytruda
compani lowest expect growth sumitomo taisho
sumitomo group see loss us latuda earli
analysi yet model vant deal close earli
give sumitomo stake five us-bas vant subsidiari
least hold parent roivant deal expect bring right
relugolix pre nda uterin fibroid evalu consensu sale
across uterin fibroid endometriosi earlier
year lead indic uterin fibroid seen mix also bring
vibegron over-act bladder anoth product evalu consensu
data suggest sale yet japanes team
model transact
taisho see overal littl growth luselfi boniva off-set
declin clarith geninax
oper margin line index drug sale -econom bar establish drugsrec lchespipelin inc sale probhealth/pharma charl martineau univers toronto
figur breakdown sale molecul type
oper margin line index group sale -rep bar drug salesoth salesgroup margin line brand drug salessmal moleculesimpl biologiccomplex biologicvaccin biosimilar gene therapi cell therapyhc op charl martineau univers toronto
use pharmavalu databas highlight sourc top-lin growth
pharmavalu compris individu market pipelin
product combin global brand pharma sale
past four year revenu growth cohort
medicin grown averag per annum forecast sale compound-annual-growth-rate
figur set growth broad therapeut
categori
key therapeut class domin growth forecast
increment brand pharma revenu
major deriv oncolog immuno-inflamm rare diseas glp-
class diabet case therapeut class split across
therapeut code within pharmavalu psoriasi dermatolog crohn
gi bring togeth figur
oncolog engin growth estim
oncolog gener increment sale repres total
industri increment brand pharma sale time-frame forecast
tradit oncolog agent chemotherapi hormon agent target
biolog exclud immunotherapi grow per annum
forecast haem-oncolog categori blood cancer declin rate
per annum due drag gener glivec biosimilar rituxan
driver growth revlimid celgen imbruvica darzalex
genmab venclexta roch newli approv calquenc azn
addit forecast immuno-oncolog mainli driven
merck roch azn car-t therapi grow per
annum grown averag sinc forecast
target oral cancer categori grow per annum driven
second-largest contributor
increment revenu forecast total immuno-inflamm
revenu domin legaci biolog rheumatoid
arthriti categori sale multipl sclerosi sale
forecast ra biolog categori show declin owe entri
biosimilar anti-tnf set impact sale despit gener
entri ms gilenya copaxon forecast growth driven
new therapi ocrevu ofatumumab outsid categori
forecast strong growth emerg new immuno-inflamm
categori psoriasi atop dermat ibs/crohn new oral immune-
modulatori drug drive signific growth estim
forecast sale categori approxim doubl
diabet inhibitor also major growth driver respons
increment sale compound-annual-growth-rate growth driven
market share gain oral diabet therapi insulin driven
superior once-weekli administr growth continu
domin ozemp novo nordisk trulic well newli
launch rybelsu expect peak sale
alzheim nash/obes emerg new driver growth
expect market entri new product larg potenti market
opportun alzheim resurrect aducanumab driven
growth estim show compound-annual-growth-rate growth
increas probabl success current obes drug novo
saxenda seen modest sale date owe minim weight-loss effect
expect next-gener obes drug greater efficaci uplift growth
forecast growth compound-annual-growth-rate obes base compar
nash compound-annual-growth-rate growth rate calcul howev model show
expect sale
kidney diseas anaemia anoth evolv area growth
transit use rel low-cost epo erythropoietin potenti use
hif-ph
otsuka/akebia/vifor daprodustat gsk treat anaemia associ
chronic kidney diseas ckd approxim one-fifth us medicar healthcar
spend current use kidney diseas key area unmet need
expect increas focu new therapi model compound-annual-growth-rate growth
anticip entri therapi back declin
figur set exposur global major pharma univers six
key therapeut revenu driver new oncolog oncolog new immuno-
inflamm rare diseas vaccin
continu includ haemophilia rare diseas captur growth
contribut hemlibra roch merck reli new oncolog
product drive growth wherea roch greater depend
oncolog asset rituxan avastin herceptin drive growth
slow biosimilar eros also includ vaccin separ
categori illustr key growth driver gsk sanofi merck overal
forecast total vaccin sale increas per annum line
figur exposur therapeut categori growth driver major pharma
compani data credit suiss estim merck base evalu consensu
figur therapeut categori revenu assumpt time
sourc growth immuno inflamm oncolog new po immuno ex charl martineau univers toronto
figur therapeut categori detail revenu assumpt time
gener exposur remain import theme pharma particularli
grow impact biosimilar product risk drug sale
biolog product risk gener competit
biolog risk biolog
highlight figur howev look year expect see
brand drug sale loss impact financi result delay
patent loss affect onward reflect time
gener entri assumpt biolog eros affect multipl year
contrast faster small-molecul eros
figur total product valu risk year patent expiri
figur actual/expect revenu eros time patent expiri
figur figur highlight aggreg forecast five key
complex product expect face biosimilar competit next
year total forecast biolog gener global sale excess
forecast sizeabl eros brand sale univers
europ biosimilar market becom success
see adopt rate major european countri pick
decad initi introduct
price reduct biosimilar vari significantli across europ
centralis tender market nordic biolog experienc
signific fast price eros compar believ
typic non-tend market germani level price eros
depend number entrant humira germani octob
first biosimilar amgevita enter discount follow quickli
imraldi discount third entrant hyrimoz
sandoz/novarti initi launch line imraldi quickli took
discount model gener eros continu assum
medium eros rate sale plateau around pre biosimilar entri
level global basi reflect increas utilis biolog
new lower price point post biosimilar entri ra drug humira
enbrel less life-sav cancer drug
us potenti impact biosimilar remain less clear
us biosimilar market begin open although penetr far
modest detail earli sale data key us drug figur figur
gener still see limit payer incent move biosimilar although
note unit health announc octob would prefer
use biosimilar avastin herceptin brand well
remicad jnj remicad first major opportun despit two
competitor pfizer inflectra list price discount novemb follow
samsung bioepi renflexi list price discount juli seen
limit eros even list price rise base brand remicad list price pre-
biosimilar per vial march septemb
avastin roch saw first us biosimilar competit august avastin
impact sale minim see competit ramp
announc launch decemb
herceptin also launch biosimilar juli
announc expect launch februari roch signal
would affect contract ahead expect gener entri saw
declin sale howev gener avail sale fell yoy
figur possibl sub cut dose roch may abl trade
risk patent loss mus-moleculeex us-moleculeus-biologicex eros cs forecast us small molecul ex us small charl martineau univers toronto
higher-brand drug cost lower overal cost shorter hospit visit
rituxan expect launch januari
humira impact biosimilar humira remain key question given size
drug us know
number biosimilar alreadi line six stagger launch agre
start januari novemb note
momenta decid august year shelv biosimilar develop
fail find suitabl commerci partner
metric look proport pharma sale expect
erod patent expiri data taken
earn model consid eros loss sale post patent expiri
show expect sale loss separ give
idea near-term vs mid-term risk
dot line extens bar company-level data show worst-cas
scenario base eros us sale ex-u sale beyond
actual eros forecast patent expiri worst-cas
scenario would small increment gener eros
model howev complex gener biosimilars/respiratori
may model limit eros brand worst-cas increment would
signific score compani base expect exposur
avastin us biosimilar marketavastin gross mvasi remicad us biosimilar market remicadeinflectrarenflexisclass net sale neulasta us biosimilar marketneulastafulphilaudenycatot net herceptin us biosimilar marketherceptinherceptin charl martineau univers toronto
limit new patent expiri next year gsk score highest
follow azn novo sanofi
gsk look best place term new patent loss wave hiv
drug patent howev yet feel full forc us advair
patent loss one gener limit capac today also yet
seen loss us gener ventolin hfa addit risk shown includ
possibl loss benlysta iv post possibl expiri
compani highest percentag exposur gener risk
novarti roch bayer exposur earn level mitig
scale agrochem oper
abbvi exposur on-going genericis humira ex us
expect entri gener us well known forecast base
evalu consensu estim cs extrapol shown figur
novarti key risk us gilenya formul patent appear
upheld court understand settlement negoti
on-going first filer alreadi settl long-dat term assum
probabl settlement therefor drug count
signific loss drug affect novarti score includ promacta
peak tasigna peak
bayer key patent loss xarelto us formul patent
settl unspecifi addit period
assum beyond therefor econom interest us xarelto
affect expect patent loss analysi appear
increment risk howev expect patent extens europ
expect loss bayer econom earli
compani data credit suiss estim data base evalu consensu
risk patent loss expect loss base expect loss basetheoret add loss charl martineau univers toronto
global level top scorer grifol orion sinc last year
ipsen score deterior higher visibl potenti somatulin
grifol plasma fraction barrier entri come
plasma suppli fraction distribut basic albumin ig alpha
anti trypsin product market mani year reli
tradit patent protect purchas shire takeda
larg plasma fraction csl key busi vaccin
limit patent protect sanofi offer regular
high-dos vaccin suitabl elderli without appar patent issu
merck kgaa appear score well upcom patent howev
taken account potenti loss glucophag concor sale china
glucophag concor old drug well beyond
patent shock enjoy strong on-going growth china may
risk product ad next chines govern tender
process understand suffici local compani
bioequival product allow drug ad next tender list
would like reduc price act form patent expiri given
signific merck glucophag chines sale
assum degre risk
orion although orion upcom patent expiri brand portfolio
yet experi meaning eu gener competit sed
simdax expect despit initi patent lose orion also
portfolio biosimilar brand gener respiratori drug allow
orion benefit patent expiri eu gener spiriva develop
lundbeck suffer wave patent expiri still affect
expiri onfi peak northera peak
abilifi maintena book revenu northera
patent impact group still heavi launch phase newli
ucb see two major patent loss vimpat peak sale
neupro peak cimzia also contend biosimilar
competit compet drug humira enbrel remicad establish
europ emerg us
vifor theoret risk vifor come ferinject us
risk patent loss expect loss base expect loss basetheoret add loss charl martineau univers toronto
highest-scor compani univers beigen galapago
neurocrin sarepta new portfolio drug mani year away
alexion risk come loss soliri patent ex us
us team assum strong retent franchis sale
soliri sale next gener drug ultomiri
see short-term loss neulasta gener count
analysi deem loss potenti prolia/xgeva end-
although expect stabl sale theoret
risk also emerg strong produc biosimilar give
opportun patent loss
lose royalti incom rituxan gener effect
impact us sale tecfidera ex us us
team model tecfidera exclus note broad
settlement anda filer regard gener dimethyl fumar possibl
could allow potenti gener entrant prior
regeneron direct sale eylea key patent expiri us
team model eros competit threat
biosimilar competit provid downsid risk analysi
risk patent loss expect loss base expect loss basetheoret add loss charl martineau univers toronto uncertainti time effect patent loss gilenya licens
novarti ex japan us primari patent expir august
novarti patent settlement talk regard patent current
unknown patent settlement term tanab novarti enter
arbitr proceed whether novarti need continu pay royalti
tanab post basi patent expiri tanab model
assum incom august incom novarti held
escrow disput settl
taisho expect see patent expiri group lead four
drug npv edirol boniva lusefi
loqoa tape assum eros increment sale
analysi base faster-than-expect eros
astella increment risk come faster eros betani us loss
eros lexiscan see loss sale despit
theoret patent daiichi sankyo addit risk come
possibl eros ferinject
japanes compani score compani base mix global
product product analysi bar exposur long list drug within
group domest portfolio spot rel last year biggest improv
astella move score kkirin ono
compani score best analysi daiichi sankyo kkirin
score worst analysi dainippon sumitomo tanab
taisho shionogi biggest faller sinc last year includ loss
cymbalta analysi
dainippon sumitomo increment risk forecast
come faster-than-expect eros replag japan
tanab expect patent expiri stelara co-promot
innov year expect patent expiri
invokana tanab receiv royalti remain
sale risk patent loss bar long list percentag spot expect loss base expect loss basetheoret add loss baselong list charl martineau univers toronto
chang mix specialti versu primari care drug influenc pharma
busi margin develop time cost market product
influenc number prescrib doctor level competit
sensit categori promot share voic specialist product
prescrib rel small number doctor cover
famili doctor dtc advertis managed-car formulari
negoti also increasingli import lower price effect
push patent support cost higher therefor believ compani see
shift toward specialti care like improv oper margin
similar-s compani sustain focu primari care
continu forecast shift sale toward specialti care cancer
product across total pharmavalu univers
figur forecast strongest growth sale cancer product
compound-annual-growth-rate follow gp direct primari care compound-annual-growth-rate
forecast cancer sale repres total
comparison expect patient direct primari care declin
compound-annual-growth-rate time expect slight margin expans
univers
figur sale mix shift specialty/canc
categoris drug pharmavalu four market burden bucket
primari care patient direct product prescrib famili doctor
influenc patient request encompass therapeut categori
dtc advertis heavili influenti exampl includ drug allergi erectil
dysfunct constip obes
primari care physician direct encompass drug decis
made physician rather patient dtc less relev although
like still use rais patient awar exampl includ cardiovascular
respiratori depress diabet
specialti care ex-canc product prescrib specialist physician
diagnosi treatment mani diseas beyond scope famili
doctor dealt referr smaller group highli train specialist
market done much smaller sale forc decis base
detail consider clinic data exampl includ schizophrenia multipl
sclerosi hiv
cancer one fastest-grow area specialti care spend carv
cancer separ categori purpos score includ
specialti care cancer discret market control oncologist
current prescrib heavili influenc clinic data howev year
begun see dtc advertis key drug expect oncolog
sale increas compound-annual-growth-rate given high number
broadli equival product class expect price
pressur emerg current product differenti base subtl
differ clinic data limit direct overlap forc
price competit assum structur chang us profit
remain high control limit compar primari care nevertheless
protect categori classif remov medicar part
product switch part price pressur could materialis even cancer
addit high on-going cost oncolog new indic
combin could act drag profit
sale categori compar across compani time
score paramet year focus chang portfolio mix
typic specialti cancer product profit owe
higher price compar primari care product therefor shift toward
specialti could foreshadow margin leverag assum base level critic mass
global level top two scorer azn roch posit scorer
includ novarti
azn score highli owe expect growth proport
specialty/canc product drug sale rel major
pharma peer averag vs averag growth primarili driven
cancer franchis includ tagrisso imfinzi calquenc lynparza
highlight tagrisso small molecul indic egfr nsclc
key driver view like extrem profit owe lack
competit view transit azn pipelin focu facilit
margin leverag forecast margin increas
exclud externalis incom vs major peer
roch also score highli major portfolio drug sale come
specialty/canc drug expect absolut total remain flat
see proport cancer drug sale declin
due biosimilar eros avastin herceptin rituxan expect
off-set growth specialti product includ hemlibra haemophilia
ocrevu multipl sclerosi pipelin drug risdiplam oral therapi
sma etrolizumab biolog irrit bowel diseas
global level lowest scorer novo nordisk follow bayer
novo score poorli owe increas focu primari care
diabet simultan shrink specialti care busi haemophilia
lead declin total specialti care drug sale novo
haemophilia franchis continu declin introduct new product
hemlibra limit novoseven use mainli surgeri mani market
time expect lower margin diabet busi
upcom launch rybelsu oral semaglutid primari care set
us start earnest
bayer see declin proport sale specialti care owe
increas competit haemophilia betaseron multipl sclerosi
kogen brand still carri costli market burden partial
off-set xarelto growth eu longer us
show slight declin total specialty/canc period
absolut total higher peer given solid oncolog imbruvica darzalex
immunolog stelara tremfya grow neurolog spravato franchis
figur chang sale mix time
global level top scorer almiral ipsen vifor grifol
almiral show greatest expect improv proport sale
specialist care drug score well
market burden metric growth driven tirbanibulin actin
keratosi specialti dermatolog product includ lebrikizumab
partner dermira biolog atop dermat expect
launch
ipsen proport sale specialist/canc drug
remain roughli flat overal higher peer palovaroten potenti market
entri would add specialti sale although recent revis
expect fda announc partial clinic hold may
balanc estim declin somatulin sale come increas
competit first gener competitor sandostatin lar gener
launch germani see like impact sale ahead
direct gener somatulin model potenti
europ us
figur specialti chang sale mix time
orion score worst categori follow lundbeck recordati
orion result contrast report one highest
score term market burden pivot place
chang period reflect reduct sale forecast
nubeqa darolutamid prostat cancer base view
lundbeck like orion flip top scorer last year low scorer
year drop proport specialti product owe
expect gener eros northera loe success launch
eptinezumab migrain foliglurax parkinson could help bolster
figur biotech chang sale mix time
figur japan pharma chang sale mix time
chang product concentr key driver margin develop time
view product oper leverag often overlook pharma industri
eventu blockbust product reach scale increment market
invest necessari sustain sale point increment sale fall directli
bottom line pre-r basi may gener contribut
margin believ compani see shift toward increas
product concentr like improv oper margin one
similar size diversifi portfolio assum primary/secondari
care mix similar
emerg diagnostically-select patient popul one notabl
industri trend advent mini-bust rel specialti
drug achiev megabrand profit driven limit market requir
often high price mini-bust key focu pharmaceut
industri challeng investor understand mani
diversifi driver revenu
figur show chang product concentr univers
forecast contribut drug repres industri
sale compar valu drug annual sale
forecast fall industri sale base cs
forecast evalu consensu us major
figur chang industri product concentr time
top product time
figur set top global product pharmavalu databas
look expect increment
revenu top drug versu gain driven growth
keytruda cancer merck revlimid cancer eliqui cardiolog
 tagrisso cancer azn emerg new top product
franchis outsid top analysi includ tagrisso darzalex
immunoglobulin ozemp rybelsu count singl
semaglutid franchis would rank fifth-biggest drug combin revenu
figur top drug time
 drugssal drug smallernumb charl martineau univers toronto
retain highest score product concentr fourth year
run top-fiv drug account revenu
period continu growth eliqui expans opdivo
new indic notabl adjuv immune-oncolog off-set declin
revlimid patent expiri
astrazeneca continu show signific improv year analysi
revenu contribut top-fiv drug growth tagrisso imfinzi
farxiga remain signific contributor period lynparza
also becom major contributor tagrisso see major contribut
addit indic adjuv egrfm nsclc well strong em
growth forecast signific opportun adjuv lung bladder
imfinzi heart failur farxiga
novo nordisk score improv year launch rybelsu bolster
drug sale give posit above-averag product
figur chang product concentr time
gsk novarti lowest product concentr major pharma
univers slightli declin product concentr
howev see balanc posit margin trend gsk see growth
shingrix offset declin advair tivicay gsk invest
build oncolog franchis follow tesaro acquisit expect
dilut product concentr off-set higher margin come
cancer drug novarti growth cosentyx zolgensma compani
highest-margin product entresto mekinist/tafinlar offset declin gilenya
afinitor also note howev expect sanofi new cfo narrow
focu fewer therapeut area current around eight would expect
product concentr increas result select busi segment
roch score averag owe fall proport top-fiv drug
howev note increas
margin period attribut grow focu new
oncolog product high-margin rare-diseas product
compani data credit suiss estim us major shown asterisk base data evalu consensu cs estim
around drug sale top-fiv drug specialti pharma group
score posit compar major pharma drug sale reflect
smaller sale market infrastructur relianc often less
grifol score highest owe specialis blood product
see top-fiv concentr increas respect
result increas sale immunoglobulin albumin csl flu
vaccin also remain signific contributor revenu
recordati orion score lowest top-fiv concentr
respect versu averag recordati top-four drug
zanidip urorec toprol signifor remain unchang orion
growth easyhal franchis nubeqa off-set declin simdax
comtan lesser extent dexdor
figur chang product concentr time
lundbeck also score well owe fast grow sale rexulti trintellix
launch eptinezumab off-set fall sale lexapro
includ almiral analysi first time score averag
owe materi lower top-fiv drug concentr despit strong increas
concentr period driven grow sale seysara
skilar ilumetri tirbanibulin amount
ucb see vimpat patent expiri result observ step-down
figur biotech chang product concentr time
figur japan pharma chang product concentr time
probabl launch
pipelin compound take standard valu stage develop
modul reflect data specif drug includ clinic data seen far
therapeut area problem experienc similar product compani track
record compar regularli pharmavalu probabl success rate
industri sourc parexel biopharmaceut statist sourc
book market drug probabl launch
repres first launch date product key drug usual separ
revenu potenti major geograph region us europ japan reflect
first launch geographi
multipl point sale curv driven directli drug revenu assumpt
compani model outsid normal model rang use algorithm
best-fit curv last model revenu point life-cycle assumpt
credit suiss global pharmaceut team assess maximum sale
potenti given product given indic specif region sale forecast
us million
driven larg gener entri year competit environ
therapeut categori drug exampl major competitor go gener could
limit growth anoth brand mani year patent expiri peak sale
year defin start sale plateau
product reach peak sale potenti may show limit growth
patent expiri credit suiss forecast revenu growth less assum
discount rate assum product plateau
driven composit matter patent us orang book equival
european patent moder addit exclus protect orphan
drug supplementari protect certif devic patent relev inhal
drug pen devic unknown patent date pipelin drug patent restor
expect yet grant assum gener entri year launch
import note sometim gener entri date correspond
quot patent expiri date special case patent challeng
concern valid may use earlier gener entri date similarli regulatori
issu absenc approv gener may push gener entri date beyond
control rate declin sale follow gener entri input select
rate includ molecul type biolog slower small molecul
geograph region us faster eu japan slowest
calcul pharmavalu npv input averag margin product
life-cycle estim margin tax within algorithm averag
margin interpol progress across remain life-cycle take account
launch invest earli year supranorm profit plateau/peak
period typic averag margin larg pharma drug primari care set
may reduc in-licens royalti paid therapeut area
particularli competit specialti drug uniqu product high innov
averag life-cycle margin could consider higher compani sum
individu product margin check consist last report pharma
margin pre-r project margin check forecast
advantag pharmavalu npv approach
limit pharmavalu npv approach
look contribut individu drug pharmavalu
highlight rel import product compani unlik short-term
earn pharmavalu npv reflect sustain contribut
base time patent expiri mani case largest short-term earn
driver major contributor npv eg gilenia novarti us advair
gsk major drug near-term patent expiri
pharmavalu valu pipelin project basi market drug
valu modul base clinic data regulatori timelin
becom clear develop
accommod incom stream often report turnov includ
royalti incom out-licens product intellectu properti valu
gener non-consolid drug sale eg lucenti royalti incom
novarti roch effect royalti payment azn
provid solid scenario analysi impact futur outcom drug
valu exampl drug pass develop mileston regulatori decis
also allow rapid estim individu drug valu follow shock
event withdraw owe safeti concern
pharmavalu allow pharmaceut biotech compani compar
global basi use standard algorithm methodolog one probabl
revenu assumpt product geographi critic drug
co-market provid consist approach global investor
methodolog suitabl lifecycle-bas healthcar product includ
small biotech specialti pharma major drug compani provid investor
unifi valuat approach across multipl healthcar sector across
unlik tradit dcf approach pharmavalu npv base pre-r
post-tax ebit assumpt differenti highli cash-
gener compani reinvest aggress infrastructur
particularli import specialti pharma compani decid enter new
market major infrastructur spend eg lundbeck invest enter
migrain market world-wide compani whose product manufactur capit
intens eg novo move introduc oral glp high cap exp requir
new facil
individu product margin drug life-cycle difficult predict
littl inform avail direct contribut margin product
pipelin disclosur vari compani therefor aggreg valu
